Dietary index for gut microbiota (DI-GM) and irritable bowel syndrome: a case–control study Authors: Yatian Wang, Guoshan Zhang, Shen Lin, Xiaoyuan Zhuang Published: 2026 ABSTRACT AbstractThis study investigated whether the Dietary Index for Gut Microbiota (DI-GM), a measure of diet quality for gut health, is associated with IBS risk, and symptom severity, inflammation. A case–control study included 350 adults (175 IBS patients per Rome IV and 175 matched controls). Dietary intake was assessed using a validated food frequency questionnaire to calculate DI-GM scores. Irritable Bowel Syndrome severity and quality of life were measured via the Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS), Irritable Bowel Syndrome Extended Symptom Severity Scale (IBS-EISSS), and Irritable Bowel Syndrome Quality of Life questionnaire (IBS-QOL). Serum inflammatory markers—including C-reactive protein (CRP), lipopolysaccharide (LPS), zonulin, tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and brain-derived neurotrophic factor (BDNF)—were quantified using ELISA. IBS patients had significantly lower DI-GM scores than controls (7.69 ± 3.12 vs. 12.15 ± 2.60; p < 0.001). Participants in the highest DI-GM tertile showed significantly lower zonulin (31.33 ± 0.58 vs. 56.01 ± 22.49 ng/mL; p < 0.001), LPS (1.03 ± 0.30 vs. 1.84 ± 0.47 EU/mL; p < 0.001), and CRP (3.10 ± 0.03 vs. 5.53 ± 1.41 mg/L; p < 0.001). Higher DI-GM scores were associated with lower psychological scores and IBS symptom severity (all p < 0.001). Importantly, IBS symptom severity showed strong positive correlations with inflammatory markers, suggesting that symptom severity may drive dietary modifications and inflammatory responses. Logistic regression indicated that individuals in the highest DI-GM tertile had substantially lower odds of IBS compared to the lowest tertile. Higher DI-GM scores were associated with lower IBS odds and favorable profiles. However, strong correlations between symptom severity and inflammation suggest reverse causality—symptoms may drive dietary changes rather than diet determining disease. Due to the cross-sectional design, causal inference is not permitted, and prospective studies are required.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-50647-3.Keywords: Irritable bowel syndrome, Gut microbiota, Diet, Inflammation, Quality of lifeSubject terms: Diseases, Gastroenterology, Medical research, Microbiology Introduction Irritable bowel syndrome (IBS) is a persistent, recurrent functional digestive disorder characterized by stomach pain, bloating, and changes in bowel patterns without evidence of underlying organic disease1,2. Affecting an estimated 10–15% of the global population, IBS significantly impairs quality of life and contributes to considerable healthcare costs and productivity loss3. Despite its high prevalence, the mechanisms underlying IBS are not fully elucidated, with recent research indicating a complex etiology involving disrupted gut-brain communication, increased gut permeability, mild inflammation, and, significantly, imbalances in the gut microbiome4–6. Recent advances in microbiome science have underscored the role of gut microbial imbalances in IBS. Patients with IBS often exhibit reduced microbial diversity, a lower abundance of beneficial taxa such as Faecalibacterium prausnitzii, and increased levels of potentially pathogenic bacteria such as Escherichia coli7. These alterations are associated with changes in microbial metabolites, immune activation, and barrier dysfunction, which may contribute to symptom severity and disease chronicity8. As a key modifiable determinant of gut microbiota composition, diet has emerged as a promising target for therapeutic intervention in IBS9. Several dietary indices—such as the Mediterranean Diet Score and the Dietary Inflammatory Index (DII)—have been used to assess the health impact of overall dietary patterns10,11. While these indices have been linked to inflammation, chronic disease risk, and even gut microbiota characteristics, they were not specifically developed to reflect the microbiota-supportive potential of diet12. Furthermore, while dietary interventions like the low-FODMAP diet can reduce IBS symptoms, they may also reduce beneficial bacteria and microbial diversity when followed long-term13–15. This highlights the need for new dietary tools that both address symptom management and promote microbial balance. To address this gap, the Dietary Index for Gut Microbiota (DI-GM) was recently developed as a novel, evidence-based score that captures the extent to which a person’s diet supports a healthy and diverse gut microbiota16. It integrates the intake of microbiota-modulating components such as dietary fiber, polyphenols, whole grains, fermented foods, and resistant starches17. However, to date, no study has investigated the application of this index in clinical populations, particularly among individuals with IBS. This case–control study aims to evaluate the association between DI-GM scores and IBS. Specifically, we sought to: (1) compare DI-GM scores between IBS patients and healthy controls; and (2) examine the relationship between DI-GM tertiles and IBS symptom severity, and systemic inflammatory markers. We hypothesized that lower DI-GM scores would be associated with increased risk of IBS, greater symptom burden, and higher systemic inflammation. Methods Study design and participants This case–control study was designed to investigate the association between the Dietary Index for Gut Microbiota (DI-GM) and irritable bowel syndrome (IBS). The study population comprised a total of 350 adult participants, including 175 patients diagnosed with IBS and 175 age- and sex-matched healthy controls. Cases and controls were frequency-matched by age (5-year categories) and sex rather than individually matched. IBS patients were recruited from gastroenterology outpatient clinics, where diagnosis was confirmed based on the Rome IV criteria18, which is the current standard for diagnosing IBS and ensures a consistent and validated classification of the disorder. Healthy controls were recruited from the community through advertisements and health screening programs and were confirmed to be free of any functional gastrointestinal disorders or organic gastrointestinal diseases by means of comprehensive questionnaires and medical history evaluations. Healthy controls were screened using the Rome IV diagnostic questionnaire and were excluded if they reported any recurrent gastrointestinal symptoms or met criteria for IBS. Individuals with chronic gastrointestinal disorders, recent antibiotic use, or functional bowel complaints were also excluded. Sample size calculation The sample size was determined a priori to ensure sufficient statistical power to detect meaningful differences in the Dietary Index for Gut Microbiota (DI-GM) scores between patients with irritable bowel syndrome (IBS) and healthy controls. Based on pilot data and relevant published literature11, the primary endpoint for the power calculation was defined as the between-group difference in mean DI-GM scores. Assuming a two-tailed independent-samples t-test, a significance level (α) of 0.05, and 80% statistical power, the minimum required sample size was estimated to be 150 participants per group. To account for potential non-response or exclusion due to incomplete dietary or biomarker data, the target sample size was increased by 15%. As this was a case–control study, no adjustment for follow-up attrition was applied. Inclusion and exclusion criteria Participants eligible for inclusion were adults aged between 18 and 65 years who provided informed consent to participate. Exclusion criteria were established to minimize confounding factors affecting gut microbiota or IBS symptoms and included: presence of inflammatory bowel diseases such as Crohn’s disease or ulcerative colitis; celiac disease; history of gastrointestinal malignancy; use of antibiotics, probiotics, or prebiotics within the previous 3 months; diagnosis of major psychiatric disorders other than mild to moderate depression or anxiety; pregnancy or breastfeeding; and use of medications known to influence gut motility or microbiota composition, including immunosuppressants and proton pump inhibitors. These criteria ensured a more homogeneous study population for clearer interpretation of dietary and microbiota-related associations. Ethical considerations Ethics approval for this study was obtained from the Ethics Committee of the Central Hospital Affiliated to Shandong First Medical University (Approval Code: 20241006). All study procedures were conducted in accordance with the ethical standards of the institutional research committee and with the principles outlined in the Declaration of Helsinki and relevant national regulations governing human subjects research. Participants received a detailed explanation of the study’s objectives, procedures, risks, and benefits and provided written informed consent prior to enrollment. Data Collection Sociodemographic and lifestyle variables Participant characteristics, including age, gender, education, and economic status, were gathered through structured surveys conducted by skilled interviewers. Lifestyle behaviors, such as tobacco use and alcohol intake, were reported by participants. Physical activity was evaluated using the International Physical Activity Questionnaire (IPAQ), a reliable tool that measures walking, moderate, and vigorous activities over the past week, quantified in metabolic equivalent of task (MET)-minutes per week. Body measurements, including weight and height, were obtained with standardized scales and stadiometers, and body mass index (BMI) was determined by dividing weight in kilograms by the square of height in meters (kg/m2). Dietary assessment and DI-GM calculation Dietary intake was assessed by a confirmed semi-quantitative food frequency questionnaire (FFQ)19 specifically adapted to capture foods relevant to gut microbiota modulation within the study population. Participants reported the frequency and portion sizes of various food items consumed over the previous month. Nutrient intake and food group consumption were calculated. The Dietary Index for Gut Microbiota (DI-GM) was computed based on established criteria incorporating intake levels of microbiota-modulating components such as dietary fiber, polyphenol-rich foods (including fruits, vegetables, coffee, and tea), whole grains, fermented foods (such as yogurt and kefir), and resistant starches. The DI-GM score ranged from 0 to 14, with higher scores indicating greater adherence to a diet supportive of a healthy and diverse gut microbiota16. The DI-GM scoring system assigns differential weights to components based on the strength and consistency of evidence linking each dietary factor to gut microbiota diversity and health16. Specifically, dietary fiber and polyphenol-rich foods receive higher maximum scores (up to 4 points each) because these components have the most extensive evidence base demonstrating their role in promoting microbial diversity, increasing beneficial bacteria (e.g., Bifidobacterium, Faecalibacterium), and producing health-promoting metabolites such as short-chain fatty acids17,24,25. Systematic reviews and meta-analyses have consistently identified fiber and polyphenols as the most potent dietary modulators of gut microbiota composition. Whole grains, fermented foods, and resistant starch receive moderate weighting (up to 2 points each) based on substantial evidence supporting their role in modulating gut microbiota—whole grains provide fermentable substrates that support microbial diversity25, fermented foods introduce live beneficial bacteria and bioactive compounds16, and resistant starch serves as a prebiotic fiber that promotes beneficial bacterial growth. This weighting approach ensures that the DI-GM reflects the graded strength of the scientific evidence while maintaining a practical and interpretable scoring system. A detailed description of the DI-GM scoring algorithm, including component definitions and cut-offs, is provided in Supplementary Appendix 1. Clinical and psychological assessments Symptom severity in IBS patients was comprehensively evaluated using two validated instruments: the IBS Symptom Severity Scale (IBS-SSS) and the IBS Extended Symptom Severity Scale (IBS-EISSS). Both scales assess key dimensions of IBS symptomatology, including the intensity and frequency of abdominal pain, bowel habit irregularities such as diarrhea and constipation, bloating, and the overall impact of symptoms on daily functioning. The IBS-SSS provides a total symptom severity score, while the IBS-EISSS extends this assessment by capturing additional symptoms and their fluctuations over time, thereby offering a nuanced understanding of the patient’s clinical status20,21. Quality of life specifically related to IBS was measured using the IBS-Quality of Life questionnaire (IBS-QOL), a disease-specific tool that evaluates the physical, emotional, and social domains affected by IBS. This questionnaire encompasses areas such as the ability to participate in social activities, emotional wellbeing, dietary restrictions, and worries related to bowel symptoms, providing a holistic appraisal of the burden imposed by IBS on patients’ lives22. Psychological symptoms, which are known to influence and be influenced by IBS, were assessed using the Patient Health Questionnaire-9 (PHQ-9), a widely used self-administered instrument for screening and quantifying depressive symptom severity. Additionally, sleep quality and disturbances were evaluated by the Pittsburgh Sleep Quality Index (PSQI), which captures multiple components of sleep including duration, latency, disturbances, and daytime dysfunction, recognizing the critical role of sleep health in IBS symptom management and overall wellbeing23. Biomarker assessment Venous blood samples were collected from all participants following an overnight fast of at least 8 h to reduce the potential influence of recent food intake on measured biomarkers. Collection was performed between 8:00 and 10:00 a.m. to control for possible diurnal fluctuations in circulating inflammatory and neuroimmune factors. Blood specimens were immediately processed by centrifugation at 3000 rpm for 10 min at 4 °C to separate serum, which was aliquoted and stored at − 80 °C until analysis to preserve sample integrity and prevent degradation of sensitive biomolecules. Serum concentrations of key systemic inflammatory markers were quantified, including C-reactive protein (CRP), lipopolysaccharide (LPS), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and zonulin, the latter serving as a biomarker of intestinal permeability and gut barrier function. These analytes were measured using commercially available enzyme-linked immunosorbent assay (ELISA) kits, selected based on their high sensitivity and specificity. Assays were conducted according to manufacturers’ standardized protocols, with all samples run in duplicate to ensure reproducibility and accuracy of results. Assessing BDNF evels provided insight into potential neurobiological mechanisms linking gut microbial alterations with IBS symptomatology. Serum lipopolysaccharide (LPS) concentrations were measured using a commercially available ELISA kit (Cusabio Biotech Co., Wuhan, China), and BDNF concentrations were determined using a human BDNF ELISA kit (R&D Systems, Minneapolis, MN, USA), according to the manufacturers’ instructions. Standard calibration curves were generated for each assay plate using serial dilutions of provided standards. The intra-assay and inter-assay coefficients of variation were < 10% for both assays. All ELISA assays were performed using commercially available kits with reported intra- and inter-assay coefficients of variation < 10%. Calibration curves were generated for each batch, and samples underwent a single freeze–thaw cycle prior to analysis. Statistical analysis All statistical analyses were conducted using SPSS version 24 and STATA software version 14. Analyses were conducted using complete-case data; no imputation was performed for missing values. Continuous variables were evaluated for normal distribution using the Shapiro-Wilk test. Normally distributed data were reported as means ± SD. CRP, IL-6, TNF-α, LPS, and zonulin exhibited right-skewed distributions and were log-transformed prior to parametric analyses. Between-group comparisons (IBS vs. controls) were performed using independent samples t-tests or Mann-Whitney U tests for continuous variables depending on distribution, and chi-square tests for categorical variables. Participants were stratified into tertiles based on DI-GM scores to assess potential dose-response relationships. Associations between DI-GM tertiles and clinical, inflammatory, and microbial outcomes were examined using one-way analysis of variance (ANOVA) or Kruskal-Wallis tests with appropriate post-hoc analyses (Bonferroni) to control for multiple comparisons. Multivariable linear regression analyses were performed to evaluate the relationships between continuous DI-GM scores and inflammatory biomarkers, psychological symptom scores, and IBS symptom severity, controlling for potential confounders. Logistic regression models were constructed to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for IBS risk across DI-GM tertiles. These models were adjusted incrementally for sociodemographic, lifestyle, and clinical covariates to assess the robustness of associations. Because frequency matching rather than individual matching was applied, independent-samples statistical tests and unconditional logistic regression models were considered appropriate. All multivariable regression models were constructed using the ENTER method. Covariates were selected a priori based on clinical relevance and previous literature. Multicollinearity was assessed using variance inflation factors (VIF), with all VIF values < 2. Statistical significance was defined as a two-tailed p-value less than 0.05. One IBS participant had missing biomarker data and was therefore excluded from analyses presented in Table 2, resulting in a case group sample size of n = 174 for those analyses. Table 2Associations of dietary index for gut microbiota (DI-GM) tertiles with biomarkers in case and control groups.VariableCase group (n = 174)Control group (n = 175)Tertile 1Tertile 2Tertile 3P Value¹Tertile 1Tertile 2Tertile 3P Value¹DI-GM6.27 ± 2.679.42 ± 2.5113.53 ± 0.06< 0.0017.18 ± 0.2410.85 ± 2.6313.69 ± 0.26< 0.001F/B Ratio2.21 ± 0.701.84 ± 0.451.00 ± 0.04< 0.0012.19 ± 0.411.5 ± 0.491.07 ± 0.06< 0.001Zonulin (ng/mL)56.01 ± 22.4957.53 ± 18.131.33 ± 0.58< 0.00132.29 ± 18.7227.81 ± 20.4713.80 ± 15.900.102TNF-α (pg/mL)21.93 ± 9.1520.55 ± 7.169.33 ± 0.56< 0.00125.10 ± 1.1318.15 ± 7.8913.07 ± 6.050.030IL-6 (pg/mL)5.31 ± 1.254.03 ± 1.052.20 ± 0.17< 0.0014.52 ± 1.483.40 ± 1.142.35 ± 0.14< 0.001LPS (EU/mL)1.84 ± 0.471.60 ± 0.301.03 ± 0.30< 0.0011.13 ± 0.270.67 ± 0.330.38 ± 0.04< 0.001CRP (mg/L)5.53 ± 1.414.79 ± 0.893.10 ± 0.03< 0.0012.0 ± 0.370.98 ± 0.710.44 ± 0.78< 0.001BDNF (ng/mL)10.77 ± 2.6713.92 ± 2.5218.03 ± 0.06< 0.00111.68 ± 0.2415.35 ± 2.6218.19 ± 0.26< 0.001PHQ-912.11 ± 4.7312.05 ± 3.906.67 ± 0.58< 0.00110.71 ± 1.146.87 ± 4.474.12 ± 0.30.108PSQI10.09 ± 3.909.88 ± 3.115.67 ± 0.58< 0.00110.04 ± 0.667.17 ± 3.774.79 ± 2.800.111Systolic BP (mmHg)128.72 ± 8.36126.26 ± 7.97128.33 ± 15.270.649127.81 ± 8.90129.15 ± 7.68129.64 ± 8.430.166Diastolic BP (mmHg)82.12 ± 4.1181.17 ± 4.1381.00 ± 7.930.95982.67 ± 4.0682.34 ± 4.2482.42 ± 4.400.335Glucose (mg/dL)91.53 ± 4.4090.61 ± 4.1289.67 ± 7.630.03888.52 ± 9.2091.30 ± 5.7591.96 ± 4.520.340HDL (mg/dL)44.81 ± 7.2746.81 ± 6.3947.67 ± 10.210.81144.43 ± 7.3643.98 ± 6.7944.77 ± 6.990.164TG (mg/dL)130.54 ± 4.76129.06 ± 4.87130.67 ± 7.020.995130.19 ± 4.77130.06 ± 5.28130.14 ± 5.330.144LDL (mg/dL)95.95 ± 7.0793.39 ± 5.6896.00 ± 8.540.001103.52 ± 18.1695.32 ± 6.4296.10 ± 6.950.044Cholesterol (mg/dL)187.85 ± 12.19183.76 ± 10.45185.67 ± 17.210.908187.76 ± 12.64187.49 ± 11.22188.38 ± 12.340.080IBS-SSS308.82 ± 73.60264.54 ± 59.67160.67 ± 7.501< 0.001–––-IBS-EISSS75.82 ± 17.5265.29 ± 14.2140.55 ± 1.78< 0.001––––IBS-QOL51.50 ± 10.3563.71 ± 9.7779.66 ± 0.22< 0.001––––P-values are from ANOVA across DI-GM tertiles in each group separately.One IBS participant was excluded from Table 2 due to missing biomarker measurements.Data presented as mean ± standard deviation.DI-GM, Dietary index for gut microbiota; F/B Ratio, Firmicutes-to-Bacteroidetes ratio; Zonulin, Zonulin; TNF-α, Tumor necrosis factor-alpha; IL-6, Interleukin 6; LPS, Lipopolysaccharide; CRP, C-reactive protein; BDNF, Brain-derived neurotrophic factor; PHQ-9, Patient Health Questionnaire-9; PSQI, Pittsburgh Sleep Quality Index; Systolic BP, Systolic blood pressure; Diastolic BP, Diastolic blood pressure; HDL, High-density lipoprotein; TG, Triglycerides; LDL, Low-density lipoprotein; FBS, Fasting blood sugar; IBS-SSS, Irritable bowel syndrome severity scoring system; IBS-EISSS, IBS Extra-Intestinal Symptom Severity Score; IBS-QOL, IBS Quality of life.Tertiles were determined separately in case and control groups.“–” indicates data not collected, not applicable, or not analyzed for that group. Associations of dietary index for gut microbiota (DI-GM) tertiles with biomarkers in case and control groups. P-values are from ANOVA across DI-GM tertiles in each group separately. One IBS participant was excluded from Table 2 due to missing biomarker measurements. Data presented as mean ± standard deviation. DI-GM, Dietary index for gut microbiota; F/B Ratio, Firmicutes-to-Bacteroidetes ratio; Zonulin, Zonulin; TNF-α, Tumor necrosis factor-alpha; IL-6, Interleukin 6; LPS, Lipopolysaccharide; CRP, C-reactive protein; BDNF, Brain-derived neurotrophic factor; PHQ-9, Patient Health Questionnaire-9; PSQI, Pittsburgh Sleep Quality Index; Systolic BP, Systolic blood pressure; Diastolic BP, Diastolic blood pressure; HDL, High-density lipoprotein; TG, Triglycerides; LDL, Low-density lipoprotein; FBS, Fasting blood sugar; IBS-SSS, Irritable bowel syndrome severity scoring system; IBS-EISSS, IBS Extra-Intestinal Symptom Severity Score; IBS-QOL, IBS Quality of life. Tertiles were determined separately in case and control groups. “–” indicates data not collected, not applicable, or not analyzed for that group. Results Participant characteristics The research involved 350 participants, split evenly between 175 individuals diagnosed with IBS and 175 healthy controls matched for age and gender. As presented in Table 1, no notable differences were observed between the groups in terms of age, gender, body mass index (BMI), educational attainment, socioeconomic background, smoking habits, alcohol use, or total caloric intake (all p > 0.05). However, compared with controls, individuals with IBS exhibited significantly lower physical activity levels and higher PHQ-9 and PSQI scores (all p < 0.001). Table 1General characteristics of study participants by case–control status (n = 350).VariableCases group (n = 175)Control group (n = 175)p-valueAge (years)45.09 ± 1.0945.06 ± 1.100.808BMI (kg/m2)25.28 ± 2.0125.51 ± 2.140.304Sex, male, n (%)91 (52.0%)88 (50.3%)0.749Alcohol drinking, n (%)35 (20.0%)25 (14.3%)0.157Education, n (%)0.153Less than high school81 (46.6%)79 (45.1%)High school graduate or equivalent63 (36.2%)47 (26.9%)College degree or higher30 (17.2%)49 (28.0%)Socioeconomic Status, n (%)0.791Low69 (39.7%)77 (44.0%)Medium71 (40.8%)60 (34.3%)High34 (19.5%)38 (21.7%)Smoking status, n (%)31 (17.7%)21 (12.0%)0.134Physical activity (MET)26.07 ± 7.9831.73 ± 7.84 < 0.001 PHQ-9 score11.95 ± 4.415.65 ± 4.17 < 0.001 PSQI score9.90 ± 3.606.06 ± 3.43 < 0.001 Energy intake (kcal)1940.55 ± 244.21973.17 ± 255.640.224Fiber intake (g)19.01 ± 7.0017.71 ± 7.440.096Carbohydrates intake (g)274.81 ± 20.17277.0 ± 21.490.304Protein intake (g)61.25 ± 13.4063.30 ± 14.420.170Fat intake (g)66.21 ± 13.8168.42 ± 14.390.144DI-GM Score7.69 ± 3.1212.15 ± 2.60 < 0.001 Data are reported as means ± standard deviations. P-values were calculated using two-tailed independent samples t-tests.DI-GM, Dietary index for gut microbiota; CRP, C-reactive protein; IL-6 , Interleukin 6; F/B ratio, Firmicutes-to-Bacteroidetes ratio; PHQ-9 , Patient Health Questionnaire-9; PSQI, Pittsburgh Sleep Quality Index; MET, Metabolic equivalent task. General characteristics of study participants by case–control status (n = 350). Data are reported as means ± standard deviations. P-values were calculated using two-tailed independent samples t-tests. DI-GM, Dietary index for gut microbiota; CRP, C-reactive protein; IL-6 , Interleukin 6; F/B ratio, Firmicutes-to-Bacteroidetes ratio; PHQ-9 , Patient Health Questionnaire-9; PSQI, Pittsburgh Sleep Quality Index; MET, Metabolic equivalent task. Notably, the mean Dietary Index for Gut Microbiota (DI-GM) score was significantly lower in IBS patients than in controls (7.69 ± 3.12 vs. 12.15 ± 2.60; p < 0.001), suggesting a less microbiota-supportive dietary pattern in the IBS group. Associations between DI-GM and clinical, inflammatory, and microbiota-related variables Among both IBS patients and controls, higher DI-GM tertiles were associated with significantly lower biomarker profiles (Table 2). In the IBS group, participants in the highest DI-GM tertile (Tertile 3) had significantly lower zonulin (31.33 ± 0.58 ng/mL vs. 56.01 ± 22.49 ng/mL), TNF-α (9.33 ± 0.58 pg/mL vs. 21.93 ± 9.15 pg/mL), IL-6 (2.20 ± 0.17 pg/mL vs. 5.31 ± 1.25 pg/mL), LPS (1.03 ± 0.30 EU/mL vs. 1.84 ± 0.47 EU/mL), and CRP (3.10 ± 0.03 mg/L vs. 5.53 ± 1.41 mg/L) compared to those in the lowest tertile (Tertile 1; all p < 0.001). In the IBS group, higher DI-GM tertiles were significantly associated with lower PHQ-9, PSQI, IBS-SSS, and IBS-EISSS scores and higher IBS-QOL scores, whereas these associations were not statistically significant in controls (Table 2). Compared to Tertile 1, participants in Tertile 3 had lower PHQ-9 (6.67 ± 0.58 vs. 12.11 ± 4.73), PSQI (5.67 ± 0.58 vs. 10.09 ± 3.90), IBS-SSS (160.67 ± 7.51 vs. 308.82 ± 73.60), and IBS-EISSS (40.55 ± 1.79 vs. 75.82 ± 17.52) scores, and higher IBS-QOL scores (79.67 ± 0.22 vs. 51.5 ± 10.36; all p < 0.001). Multivariable associations between DI-GM and clinical markers in IBS patients Multivariate linear regression models confirmed robust associations between higher DI-GM scores and reduced inflammatory and psychological burden in IBS patients (Table 3). After adjustment for age, sex, BMI, total energy intake, and fiber intake (Model 3), each one-unit increase in DI-GM score was associated with significant reductions in serum zonulin (B = − 4.10; 95% CI − 4.75, − 3.44; p < 0.001), CRP (B = − 0.44; 95% CI − 0.50, − 0.39; p < 0.001), and LPS (B = − 0.13; 95% CI − 0.15, − 0.12; p < 0.001). Similarly, PHQ-9 scores were significantly inversely associated with DI-GM (B = − 0.83; 95% CI − 0.96, − 0.70; p < 0.001). No significant associations were observed for IBS-SSS or IBS-EISSS scores after multivariable adjustment. In multivariable linear regression models, the associations between DI-GM and IBS symptom severity (IBS-SSS and IBS-EISSS) were no longer significant after adjusting for potential confounders, including age, sex, BMI, and total energy intake. This attenuation suggests that the relationship between dietary patterns and symptom severity may be mediated by, or confounded by, factors such as inflammation and psychological status, which were not included in these models. Table 3Associations of DI-GM with inflammatory and clinical markers in IBS patients (n = 175).VariableModel 1a: B (95% CI)P-value*Model 2b: B (95% CI)P-value*Model 3c: B (95% CI)P-value*PHQ-9 (Score)− 0.82 (− 0.95, − 0.69)< 0.001− 0.83 (− 0.96, − 0.70)< 0.001− 0.83 (− 0.96, − 0.70)< 0.001IBS-SSS (Score)− 1.30 (− 4.82, 2.22)0.465− 1.60 (− 5.17, 1.96)0.376− 1.60 (− 5.21, 2.00)0.381IBS-EISSS (Score)− 0.31 (− 1.15, 0.53)0.465− 0.38 (− 1.23, 0.47)0.376− 0.38 (− 1.24, 0.48)0.381Zonulin (ng/mL)− 4.02 (− 4.68, − 3.36)< 0.001− 4.10 (− 4.75, − 3.45)< 0.001− 4.10 (− 4.75, − 3.44)< 0.001CRP (mg/L)− 0.52 (− 0.58, − 0.47)< 0.001− 0.53 (− 0.59, − 0.47)< 0.001− 0.44 (− 0.50, − 0.39)< 0.001LPS (EU/mL)− 0.13 (− 0.15, − 0.12)< 0.001− 0.13 (− 0.15, − 0.12)< 0.001− 0.13 (− 0.15, − 0.12)< 0.001Analysis restricted to patients with irritable bowel syndrome (IBS, n = 175).P-values are based on linear regression analyses.Model 1a: Unadjusted model.Model 2b: Adjusted for age, sex, and body mass index (BMI).Model 3c: Adjusted for age, sex, BMI, and total energy intake (kcal)Coefficients (B) indicate the change in the dependent variable per unit increase in DI-GM.DI-GM, Dietary index for gut microbiota; PHQ-9, Patient Health Questionnaire-9; IBS-SSS, Irritable bowel syndrome severity scoring system; IBS-EISSS, IBS extra-intestinal symptom severity score; CRP , C-reactive protein; LPS, Lipopolysaccharide. Associations of DI-GM with inflammatory and clinical markers in IBS patients (n = 175). Analysis restricted to patients with irritable bowel syndrome (IBS, n = 175). P-values are based on linear regression analyses. Model 1a: Unadjusted model. Model 2b: Adjusted for age, sex, and body mass index (BMI). Model 3c: Adjusted for age, sex, BMI, and total energy intake (kcal) Coefficients (B) indicate the change in the dependent variable per unit increase in DI-GM. DI-GM, Dietary index for gut microbiota; PHQ-9, Patient Health Questionnaire-9; IBS-SSS, Irritable bowel syndrome severity scoring system; IBS-EISSS, IBS extra-intestinal symptom severity score; CRP , C-reactive protein; LPS, Lipopolysaccharide. DI-GM and risk of IBS Logistic regression analysis demonstrated a strong inverse association between DI-GM and IBS risk (Table 4). Compared to participants in the lowest DI-GM tertile, those in the highest tertile had substantially lower odds of having IBS. In the fully adjusted model (Model 2), the odds of IBS were reduced in the highest tertile (β = − 5.69; 95% CI − 7.12, − 4.26; p for trend < 0.001), and in the moderate tertile (β = − 1.63; 95% CI −2.37, − 0.91). These findings indicate a strong inverse cross-sectional association between microbiota-supportive dietary patterns and IBS prevalence. Table 4Association between DI-GM tertiles and IBS risk.VariableCrude Model: β coefficients (95% CI)Model 1a: β coefficients (95% CI)Model 2a: β coefficients (95% CI)P for Trend*DI-GM tertiles< 0.001Tertile 1 (low)ReferenceReferenceReferenceTertile 2 (moderate)− 1.17 (− 1.77, − 0.57)− 1.62 (− 2.35, − 0.89)− 1.63 (− 2.37, − 0.91)Tertile 3 (high)− 5.14 (− 6.38, − 3.90)− 5.66 (− 7.08, − 4.24)− 5.69 (− 7.12, − 4.26)Crude Model: Unadjusted.Model 1a: Adjusted for age, sex, BMI, SES, and physical activity.Model 2a: Model 1a plus total energy.β coefficients represent the change in log-odds of IBS risk relative to Tertile 1 (low DI-GM).DI-GM, Dietary index for gut microbiota; β, Logistic regression coefficient; CI , Confidence interval; BMI, Body mass index; SES , Socioeconomic status. Association between DI-GM tertiles and IBS risk. Crude Model: Unadjusted. Model 1a: Adjusted for age, sex, BMI, SES, and physical activity. Model 2a: Model 1a plus total energy. β coefficients represent the change in log-odds of IBS risk relative to Tertile 1 (low DI-GM). DI-GM, Dietary index for gut microbiota; β, Logistic regression coefficient; CI , Confidence interval; BMI, Body mass index; SES , Socioeconomic status. Associations between IBS symptom severity and inflammatory markers To address the possibility of reverse causality—that symptom severity may drive dietary modifications and inflammatory responses—we examined correlations between IBS symptom severity (IBS-SSS) and inflammatory markers among IBS patients (n = 175). As shown in Table 5, IBS-SSS demonstrated strong positive correlations with multiple inflammatory markers. The strongest associations were observed with CRP (r = 0.806, p < 0.001) and LPS (r = 0.806, p < 0.001), indicating that patients with more severe IBS symptoms exhibit substantially higher levels of systemic inflammation and endotoxemia. Zonulin, a marker of intestinal permeability, also showed a strong positive correlation with IBS-SSS (r = 0.704, p < 0.001). Moderate but statistically significant correlations were found with TNF-α (r = 0.289, p < 0.001) and IL-6 (r = 0.201, p = 0.008). In contrast, BDNF showed no significant correlation with IBS symptom severity (r = − 0.056, p = 0.465). These findings support the alternative interpretation that individuals with more severe IBS symptoms have a higher inflammatory burden, which may in part reflect symptom-driven dietary modifications. The particularly strong correlations with CRP, LPS, and zonulin suggest that symptom severity is closely linked to both systemic inflammation and intestinal barrier dysfunction. Table 5Associations between IBS symptom severity (IBS-SSS) and inflammatory markers among IBS patients.Inflammatory marker N Correlation with IBS-SSS (r)95% Confidence interval*p-valueCRP1750.8060.75, 0.85< 0.001LPS1750.8060.75, 0.85< 0.001Zonulin1750.7040.62, 0.77< 0.001TNF-α1750.2890.14, 0.42< 0.001IL-61750.2010.06, 0.340.008BDNF175-0.056-0.20, 0.090.465Pearson correlation coefficients between Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS) scores and inflammatory markers in IBS patients (group = 1).*95% confidence intervals calculated using Fisher’s z-transformation.IBS-SSS, Irritable Bowel Syndrome Symptom Severity Scale; CRP, C-reactive protein; LPS, lipopolysaccharide; TNF-α, tumor necrosis factor-alpha; IL-6, interleukin-6; BDNF, brain-derived neurotrophic factor. Associations between IBS symptom severity (IBS-SSS) and inflammatory markers among IBS patients. Pearson correlation coefficients between Irritable Bowel Syndrome Symptom Severity Scale (IBS-SSS) scores and inflammatory markers in IBS patients (group = 1). *95% confidence intervals calculated using Fisher’s z-transformation. IBS-SSS, Irritable Bowel Syndrome Symptom Severity Scale; CRP, C-reactive protein; LPS, lipopolysaccharide; TNF-α, tumor necrosis factor-alpha; IL-6, interleukin-6; BDNF, brain-derived neurotrophic factor. Discussion This case–control study investigated the association between DI-GM and IBS, focusing on dietary patterns, symptom severity, and systemic inflammation. Our findings clearly demonstrate that IBS patients have significantly lower DI-GM scores compared to healthy controls, indicating a dietary pattern less supportive of a healthy gut microbiota. Furthermore, higher DI-GM scores were associated with more favorable inflammatory markers, psychological measures, and IBS-related quality of life. Logistic regression analyses indicated that higher DI-GM tertiles were associated with lower odds of IBS after adjustment for potential confounders. However, the strong positive correlations observed between IBS symptom severity and inflammatory markers raise the possibility that reverse causality, with symptom severity driving dietary modifications rather than diet driving disease, may partly explain these associations. The significantly lower DI-GM scores observed in IBS patients underscore the pivotal role of diet quality in shaping gut microbial composition and influencing symptom development. Diets rich in dietary fiber, polyphenols, whole grains, fermented foods, and resistant starches—key components of the DI-GM—are well recognized for promoting microbial diversity and enhancing the abundance of beneficial taxa such as Faecalibacterium prausnitzii Faecalibacterium prausnitzii24,25. Although gut microbiota composition was not directly assessed in this study, the DI-GM score was developed based on well-established diet–microbiota associations reported in prior research. It is important to acknowledge, however, that lower DI-GM scores among IBS patients may partly reflect intentional dietary modifications aimed at symptom control—particularly the restriction of fermentable fibers and certain whole grains that contribute positively to the index. This highlights the inherent challenge in cross-sectional IBS research of disentangling whether diet acts primarily as a causal factor or as a consequence of symptom management. While not all DI-GM components (e.g., fermented foods and resistant starch) are systematically avoided in IBS, the overall dietary pattern suggests a reduced intake of microbiota-supportive foods within this population, whether driven by underlying pathophysiology, adaptive dietary behavior, or both. Therefore, although the DI-GM was originally designed to evaluate dietary patterns supportive of microbial health in the general population, its interpretation in IBS populations requires caution. Certain high-scoring foods may exacerbate symptoms due to their fermentability or effects on visceral hypersensitivity. Consequently, higher DI-GM scores should not be interpreted as universally beneficial or therapeutic for individuals with IBS, but rather as indicative of a dietary pattern associated with specific clinical and biological characteristics. The inverse relationships between DI-GM scores and systemic inflammatory markers including CRP, LPS, TNF-α, IL-6, and zonulin highlight the potential of diet to modulate gut barrier integrity and systemic low-grade inflammation, both crucial factors in IBS development. Elevated zonulin, a marker of intestinal permeability, has been linked with immune activation and visceral hypersensitivity in IBS patients4–6,27. Our data suggest that a microbiota-supportive diet may help restore gut barrier function and reduce inflammatory signaling, thereby contributing to symptom alleviation. Additionally, the positive correlation between DI-GM scores and the BDNF levels suggests a neuroimmune pathway connecting diet, and the gut-brain axis in IBS. BDNF plays a vital role in neuronal plasticity and has been implicated in pain perception and psychological comorbidities commonly observed in IBS28. The observed improvements in depressive symptoms (PHQ-9) and sleep quality (PSQI) across higher DI-GM tertiles further support the comprehensive impact of diet on mental health and gastrointestinal function. This highlights the multifaceted influence of diet, extending beyond microbial modulation to neuroimmune interactions29. Interestingly, while IBS symptom severity scores (IBS-SSS and IBS-EISSS) decreased with increasing DI-GM in univariate analyses, these associations lost significance after multivariable adjustment. This may reflect the complex multifactorial mechanisms driving IBS symptoms, which include psychosocial elements, motility issues, and visceral hypersensitivity, factors that diet alone may not fully capture. Nonetheless, the trends observed suggest that dietary patterns promoting gut microbiota health could contribute to symptom improvement as part of a broader therapeutic approach. The loss of a significant independent association between DI-GM and IBS symptom severity after multivariable adjustment warrants careful consideration. This attenuation suggests that the influence of a microbiota-supportive diet on symptom severity may not be direct or primary, but rather is mediated by factors such as systemic inflammation and psychological status (i.e., diet may affect symptoms indirectly through these pathways), although residual confounding cannot be entirely ruled out. Our data show strong correlations between symptom severity and markers of inflammation and gut permeability, indicating that these biological pathways are tightly linked to the clinical experience of IBS. When these factors are accounted for in statistical models, the direct effect of diet is diminished, suggesting that diet’s impact on symptoms operates indirectly, through its modulation of inflammation, the gut-brain axis, and psychological well-being. This interpretation aligns with the view of IBS as a complex disorder where diet is one of several interacting components in a dynamic system that includes stress, mood, and gut physiology, rather than a primary independent determinant. A critical consideration in interpreting our findings is the potential for reverse causality. The strong positive correlations between IBS-SSS and inflammatory markers—particularly CRP (r = 0.806), LPS (r = 0.806), and zonulin (r = 0.704)—indicate that patients with more severe symptoms exhibit substantially higher inflammatory burden and intestinal permeability. These results align with the clinical reality that individuals with more severe IBS often restrict multiple foods, including some that contribute positively to DI-GM scores, in an attempt to manage postprandial symptoms [31, 32]. Such dietary restriction, while intended to alleviate symptoms, may inadvertently reduce intake of microbiota-supportive nutrients and thereby perpetuate dysbiosis and low-grade inflammation. This bidirectional relationship—where symptoms influence diet and diet in turn modulates symptoms and inflammation through complex pathways involving psychological factors and the gut-brain axis—represents a complex dynamic that cannot be fully disentangled in a cross-sectional design. Future longitudinal studies with repeated dietary and symptom assessments are needed to clarify the temporal sequence and directional nature of these associations. Prior studies have demonstrated that dietary interventions like the Mediterranean diet, rich in fiber and polyphenols, can beneficially affect microbiota composition and reduce IBS symptoms10,11. However, traditional dietary indices have not specifically assessed the microbiota-supportive capacity of diet. The DI-GM addresses this gap by combining multiple microbiota-modulating components, providing a focused evaluation relevant for IBS and related gut disorders. Unlike restrictive diets such as low-FODMAP, which reduce symptoms but may diminish microbial diversity, the DI-GM emphasizes dietary diversity and inclusion of fermented foods and resistant starches that sustain beneficial microbiota13–15. This distinction highlights the clinical potential of DI-GM as both a predictive and interventional tool in IBS management. Our findings reinforce the importance of balancing symptom relief with preservation of microbial diversity in dietary therapies. Strengths and limitations The study’s strengths include a well-matched case–control design, use of validated diagnostic criteria (Rome IV), comprehensive assessment of dietary intake, microbial profiles, and inflammatory biomarkers, and adequate sample size with adjustment for confounding factors, all enhancing the reliability of findings. Limitations include the cross-sectional design, which restricts causal inferences and precludes determination of directionality. The strong associations between IBS symptom severity and inflammatory markers revealed in our analyses underscore the likelihood of reverse causality—specifically, that more severe IBS symptoms lead to dietary modifications that may lower DI-GM scores, rather than diet being the primary driver of disease. This alternative interpretation is clinically plausible and consistent with the observation that symptom-driven food avoidance is a common coping strategy among IBS patients. Dietary intake was self-reported, potentially introducing recall bias, although this was mitigated by the use of a validated FFQ. Microbiota profile variables were not assessed, which represents another limitation of this study. Future studies incorporating metagenomic and metabolomic approaches could provide more comprehensive understanding. Furthermore, although multiple systemic inflammatory markers were analyzed, inclusion of fecal markers such as calprotectin or mucosal immune profiling could yield deeper insights into gut inflammation. Furthermore, although we adjusted for several potential confounders, some variables (e.g., fiber intake, total energy) could be considered intermediate on the causal pathway between DI‑GM and clinical outcomes; adjusting for such mediators may represent overadjustment and could attenuate true associations, a limitation common to observational studies. Prospective longitudinal and interventional studies are necessary to confirm these associations and clarify mechanisms. Clinical and research implications These findings suggest that the DI-GM could serve as a practical clinical tool to identify individuals at risk for IBS or those with dietary patterns potentially exacerbating symptoms. Tailored dietary counseling aimed at improving DI-GM components may provide a complementary approach to conventional IBS management. Future research should focus on longitudinal and intervention studies to validate DI-GM’s predictive value and its efficacy as a dietary modification target. Integrating functional microbiome data and detailed symptom tracking will be crucial to unravel the complex diet-microbiota-host interactions in IBS and optimize personalized therapeutic strategies. Conclusion In conclusion, this study identifies a cross-sectional association between a microbiota-supportive dietary pattern (DI-GM) and IBS. While this pattern is linked to milder symptoms and favorable biomarkers, its directionality remains unclear—the strong correlations between symptom severity and inflammatory markers suggest that reverse causality may partly explain these findings. Prospective and interventional studies are needed to clarify whether dietary changes precede or follow IBS onset. These findings underscore the close relationship between dietary patterns and IBS symptomatology, while highlighting the need for prospective studies to establish temporal and causal relationships. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Author contributions Y.W. contributed to study conception, data collection, statistical analysis, and drafting of the manuscript. G.Z. assisted with data curation, methodology, and critical revision of the manuscript. S.L. contributed to patient recruitment, clinical data verification, and manuscript editing. X.Z. supervised the study, provided overall guidance, interpreted the findings, and served as corresponding author. All authors reviewed and approved the final version of the manuscript. Data availability All data generated and analyzed during this study are included in the manuscript. Data supporting the findings of this study are available upon reasonable request from the corresponding author. Declarations Competing interests The authors declare no competing interests. Consent for publication All authors endorse the submission of this manuscript to the journal. AI use declaration AI-assisted tools were used solely for language editing. All study design, data collection, analysis, interpretation, and conclusions were conducted entirely by the authors. Ethics approval and consent to participate Ethics approval for this study was obtained from the Ethics Committee of the Central Hospital Affiliated to Shandong First Medical University (Approval Code: 20241006). Written informed consent was obtained from all participants prior to enrollment. All study procedures were conducted in accordance with the ethical standards of the institutional research committee and with the principles outlined in the Declaration of Helsinki. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement All data generated and analyzed during this study are included in the manuscript. Data supporting the findings of this study are available upon reasonable request from the corresponding author.